𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Natalizumab and central nervous system lymphoma: No clear association

✍ Scribed by Carmen Bozic; Julia LaGuette; Michael A. Panzara; Alfred W. Sandrock


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
41 KB
Volume
66
Category
Article
ISSN
0364-5134

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Primary central nervous system lymphoma
✍ Andreas Schweikert; Marcus Kremer; Florian Ringel; Thomas Liebig; Justus Duyster πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 182 KB πŸ‘ 2 views

## Abstract A 40‐year‐old man with relapsing‐remitting multiple sclerosis (MS) developed primary central nervous system lymphoma (PCNSL) after having received 21 doses of natalizumab monotherapy. PCNSL is a disease of the elderly, with the majority of patients being diagnosed in the 7th to 8th deca

Hodgkin lymphoma of the central nervous
✍ Liane Simons; Manjuvani Neerudu; Maxine Lissack; Chris McNamara πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 118 KB πŸ‘ 1 views
Telomerase activity in central nervous s
✍ Kunyu Harada; Kaoru Kurisu; Kazunori Arita; Takashi Sadatomo; Hidetoshi Tahara; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 109 KB πŸ‘ 2 views

BACKGROUND. Primary central nervous system malignant lymphoma (PCNSL) has been regarded as a rare neoplasm. Recently, however, its incidence has been rapidly increasing. Despite active clinical trials, its clinical and biologic features remain unknown and there has been no effective treatment or pro